Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Published:2020-08 Issue:8 Volume:21 Page:1057-1065
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kawazoe Akihito,Fukuoka Shota,Nakamura Yoshiaki,Kuboki Yasutoshi,Wakabayashi Masashi,Nomura Shogo,Mikamoto Yuichi,Shima Hikari,Fujishiro Noriko,Higuchi Tsukiko,Sato Akihiro,Kuwata Takeshi,Shitara Kohei

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Capecitabine and oxaliplatin for advanced esophagogastric cancer;Cunningham;N Engl J Med,2008

2. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial;Koizumi;Lancet Oncol,2008

3. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

4. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial;Wilke;Lancet Oncol,2014

5. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial;Fuchs;JAMA Oncol,2018

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics;Molecular Cancer;2024-09-13

2. Unveiling promising targets in gastric cancer therapy: A comprehensive review;Molecular Therapy: Oncology;2024-09

3. The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma;Expert Opinion on Biological Therapy;2024-08-28

4. Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges;MedComm – Oncology;2024-08-08

5. Lenvatinib acts on platelet‑derived growth factor receptor β to suppress the malignant behaviors of gastric cancer cells;Oncology Letters;2024-08-07